Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13837594 | 0.83 | CYP3A4 (0.56) | MAPK1CYP3A4MAPTTHRBABCB1 | |
| SCHEMBL13829426 | 0.82 | CYP3A4 (0.52) | MAPK1CYP3A4MAPTTHRBABCB1 | |
| SCHEMBL12573109 | 0.80 | MAPK1 (0.52) | MAPK1CYP3A4MAPTTHRBPDE4D | |
| SCHEMBL12573106 | 0.80 | MAPK1 (0.52) | MAPK1CYP3A4MAPTTHRBPDE4D | |
| SCHEMBL12573110 | 0.79 | MAPK1 (0.51) | MAPK1CYP3A4MAPTTHRBPDE4D | |
| SCHEMBL13829253 | 0.79 | ALDH1A1 (0.41) | PDE4DABCB1ALDH1A1 | |
| SCHEMBL12573080 | 0.78 | CYP3A4 (0.61) | MAPK1CYP3A4MAPTTHRBPDE4D | |
| SCHEMBL13829594 | 0.77 | MAPK1 (0.52) | MAPK1CYP3A4MAPTTHRBPDE4D | |
| SCHEMBL13829393 | 0.77 | MAPK1 (0.52) | MAPK1CYP3A4MAPTTHRBPDE4D | |
| SCHEMBL15159451 | 0.74 | CYP3A4 (0.44) | MAPK1CYP3A4MAPTTHRBPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296717-B2 | Synthesis of C-3 coupled biflavonoids and C-3 coupled biflavonoid analogues | UNIVERSITY OF THE FREE STATE (ZA) | 2016-03-29 | — | — | US | disclosed |
| US-20120289715-A1 | Synthesis of C-3 Coupled Biflavonoids and C-3 Coupled Biflavonoid Analogues | UNIVERSITY OF THE FREE STATE (ZA) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289715-A1 | Synthesis of C-3 Coupled Biflavonoids and C-3 Coupled Biflavonoid Analogues | CBR3, C9, PROC | MAPK1 1501/4885CYP3A4 115/4885MAPT 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.